Research programme: inhaled dry powder respiratory therapeutic - Novartis/MicroDose Therapeutx
Latest Information Update: 13 Jun 2014
At a glance
- Originator Novartis
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Respiratory tract disorders